Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARNCOMBI: Pfizer and Moderna COVID-19 Vaccine Interchangeability
NCT04900467Unknown
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- May 2021
- Primary completion
- Jul 2021
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Randomised, open-label trial of tozinameran and elasomeran in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Anti-Spike IgG titer at 28 days. Status: unknown.
02
Drugs
tozinameranelasomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04900467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04900467.